Susquehanna International Group, LLP Immutep LTD Put Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2025 May 14, 2025	SELL	$1.7 - $2.21 $58,650 - $76,245	-34,500 Reduced 73.09%	12,700 $22,000
Q4 2024 Feb 14, 2025	SELL	$1.82 - $2.36 $37,492 - $48,616	-20,600 Reduced 30.38%	47,200 $102,000
Q3 2024 Nov 14, 2024	SELL	$1.77 - $2.64 $96,819 - $144,408	-54,700 Reduced 44.65%	67,800 $149,000
Q2 2024 Aug 15, 2024	BUY	$1.87 - $3.23 $37,400 - $64,600	20,000 Added 19.51%	122,500 $246,000
Q1 2024 May 07, 2024	SELL	$2.11 - $2.89 $6,963 - $9,537	-3,300 Reduced 3.12%	102,500 $238,000

Q4 2023 Feb 14, 2024	SELL	$1.76 - $2.49 $68,640 - $97,110	-39,000 Reduced 26.93%	105,800 $253,000
Q3 2023 Nov 14, 2023	BUY	$1.75 - $2.37 $57,400 - $77,736	32,800 Added 29.29%	144,800 $275,000
Q2 2023 Aug 11, 2023	BUY	$1.54 - $2.62 $78,232 - $133,096	50,800 Added 83.01%	112,000 $236,000
Q1 2023 May 16, 2023	BUY	$1.63 - $2.06 $3,260 - $4,120	2,000 Added 3.38%	61,200 $102,000
Q4 2022 Feb 14, 2023	BUY	$1.6 - $2.53 $13,280 - $20,999	8,300 Added 16.31%	59,200 $103,000
Q3 2022 Nov 14, 2022	BUY	$1.56 - $2.29 $47,736 - $70,074	30,600 Added 150.74%	50,900 $79,000

2.33M

1.48K

20K

Ticker IMMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,000
Market Cap $161M
Description
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.